27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's (NASDAQ:SNY) avalglucosidase alfa for Pompe disease.
- The positive opinion is based on Phase 3 COMET study data, which showed avalglucosidase alfa improved respiratory function and movement endurance measures.
- Avalglucosidase alfa is a long-term enzyme replacement therapy designed to target the mannose-6-phosphate (M6P) receptor, the underlying disease mechanism in Pompe disease.
- The CHMP positive opinion for avalglucosidase alfa follows the EMA's acceptance of Sanofi's application at the end of 2020.
- Avalglucosidase alfa is also currently undergoing review in the U.S., U.K., and Japan. The FDA action date is August 18.
- Price Action: SNY shares are down 0.23% at $51.51 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!